Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.

ABSTRACT:

Abstract

Emicizumab improves the procoagulant activity of select loss-of-function factor IX (FIX) variants with likely dysfunctional assembly of the intrinsic Xase complex, resulting in hemophilia B (HB). FVIII mimetics may represent an alternative nonfactor therapy for select patients with HB.

SUBMITTER: Lee K 

PROVIDER: S-EPMC11419781 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature